MedX Announces Closings of First $2.5 Million of Convertible Debenture Loan Notes, & Anticipates Further Closings up to $1.5 ...
01 Fevereiro 2021 - 10:00AM
Business Wire
MedX Health Corp. (“MedX” or the “Company”)
(TSX-V: MDX) is pleased to announce that it has closed on the first
$2.5 million of the $4 million Non-brokered Private Placement of
Convertible Debenture Loan Notes each with a face value of $50,000
(“Convertible Notes”) as originally announced in its Press Release
dated January 25, 2021. On January 27 and 28, 2021, there were
closings of 40 and 10 Convertible Notes respectively, raising gross
proceeds of $2.5 million. The Convertible Notes will bear interest
at 6% per year, payable Quarterly, and will mature on December 31,
2023 (the “Maturity Date”). The Convertible Notes may be converted,
at the option of the Holder, into units at $0.14 per unit (“Unit”)
at any time until the Maturity Date. Each Unit will be comprised of
One (1) fully paid Common Share and One-half (1/2) of a Share
Purchase Warrant. Each whole Share Purchase Warrant will be
exercisable to purchase One (1) further Common Share at the price
of $0.20, exercisable for a period expiring on the Maturity Date.
The Company anticipates that it will close on further issuances of
up to 30 more Convertible Notes, for up to a further $1.5 million.
Closings will be subject to receipt of subscriptions and a number
of other conditions, including without limitation the receipt of
all relevant regulatory and Stock Exchange approvals or
acceptances. The Convertible Notes, and any underlying securities,
are subject to restriction from trading for a period of four months
and one day from the respective dates of issuance. Qualified Agents
may receive commissions in respect of subscriptions introduced by
them by way of cash equal to 6% of funds so introduced, and
issuance of agent’s warrants (“Agent’s Warrant(s)”) calculated by
reference to 6% of the funds from subscribers introduced by such
Agent. Each Agent’s Warrant, which is non-transferable, will be
exercisable to acquire one Unit at $0.14 per Unit, at any time
during the period up to the Maturity Date. In relation to the
Closings already completed, a total of $129,000 has been paid by
way of cash commissions and 407,143 Agent’s Warrants were issued.
The Agent’s Warrants, and any underlying securities, are restricted
from trading for a period of four months and one day from their
respective dates of issuance.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading
medical device and software company focused on skin health with its
SIAscopy on DermSecure™ telemedicine platform, utilizing its
SIAscopy™ technology. SIAscopy is also imbedded in its products
SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its
ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™
include hand-held devices that use patented technology utilizing
light and its remittance to view up to 2 mm beneath suspicious
moles and lesions in a pain free, non-invasive manner, with its
software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within
seconds. These products are Health Canada, FDA, TGA and CE cleared
for use in Canada, the US, Australia, New Zealand, the European
Union, Turkey and Brazil. MedX also designs, manufactures and
distributes quality photobiomodulation therapeutic and dental
lasers to provide drug-free and non-invasive treatment of tissue
damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This Media Release may contain forward-looking statements, which
reflect the Company’s current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210201005286/en/
Rob von der Porten, Chairman and Acting CEO MedX Health
Corp vonderporten@medxhealth.com
Bill Mitoulas, Investor Relations MedX Health Corp
+1.416.479.9547 bill@medxhealth.com
Medx Health (TSXV:MDX)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Medx Health (TSXV:MDX)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025